Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Original BioMedicals Co., Ltd. (6483) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.208x
Based on the latest financial reports, Original BioMedicals Co., Ltd. (6483) has a cash flow conversion efficiency ratio of -0.208x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-43.70 Million) by net assets (NT$210.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Original BioMedicals Co., Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Original BioMedicals Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Original BioMedicals Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Original BioMedicals Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TMT Steel Public Company Limited
BK:TMT
|
0.022x |
|
J8D0
F:J8D0
|
N/A |
|
Quonia SOCIMI SA
MC:YQUO
|
0.013x |
|
Grand Baoxin Auto Group Limited
PINK:GBXXY
|
0.123x |
|
MCH Group AG
SW:MCHN
|
0.108x |
|
Q linea AB
ST:QLINEA
|
-0.118x |
|
Perfect Medical Industry Co., Ltd.
TWO:6543
|
0.047x |
|
Rumble Resources Ltd
AU:RTR
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Original BioMedicals Co., Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Original BioMedicals Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$255.25 Million | NT$-84.11 Million | -0.330x | -267.01% |
| 2023-12-31 | NT$328.57 Million | NT$-29.50 Million | -0.090x | +79.58% |
| 2022-12-31 | NT$69.17 Million | NT$-30.42 Million | -0.440x | -92.44% |
| 2021-12-31 | NT$109.11 Million | NT$-24.93 Million | -0.229x | +63.77% |
| 2020-12-31 | NT$37.97 Million | NT$-23.94 Million | -0.631x | -44.59% |
| 2019-12-31 | NT$60.49 Million | NT$-26.39 Million | -0.436x | -- |